272 related articles for article (PubMed ID: 27216859)
1. Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.
Engeln M; Ansquer S; Dugast E; Bezard E; Belin D; Fernagut PO
Neuropharmacology; 2016 Oct; 109():69-77. PubMed ID: 27216859
[TBL] [Abstract][Full Text] [Related]
2. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease.
Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Oregi A; Belloso-Iguerategui A; Delgado-Alvarado M; Navalpotro-Gómez I; Marin C; Fernagut PO; Rodríguez-Oroz MC
Neurobiol Aging; 2019 Mar; 75():126-135. PubMed ID: 30572183
[TBL] [Abstract][Full Text] [Related]
3. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
4. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
5. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive study on long-term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats.
Zhou Y; Zhang Y; Li J; Lv F; Zhao Y; Duan D; Xu Q
J Neurochem; 2012 Dec; 123(5):771-80. PubMed ID: 22957701
[TBL] [Abstract][Full Text] [Related]
7. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Delgado-Alvarado M; Navalpotro-Gómez I; Belloso-Iguerategui A; Marin C; Rodríguez-Oroz MC
Psychopharmacology (Berl); 2020 Aug; 237(8):2419-2431. PubMed ID: 32440779
[TBL] [Abstract][Full Text] [Related]
8. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
9. Recruitment of calbindin into nigral dopamine neurons protects against MPTP-Induced parkinsonism.
Inoue KI; Miyachi S; Nishi K; Okado H; Nagai Y; Minamimoto T; Nambu A; Takada M
Mov Disord; 2019 Feb; 34(2):200-209. PubMed ID: 30161282
[TBL] [Abstract][Full Text] [Related]
10. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
[TBL] [Abstract][Full Text] [Related]
11. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat.
Zengin-Toktas Y; Authier N; Denizot H; Chassain C; Hafidi A; Llorca PM; Durif F
Neuropharmacology; 2013 Jul; 70():74-82. PubMed ID: 23347953
[TBL] [Abstract][Full Text] [Related]
12. Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.
Loiodice S; McGhan P; Gryshkova V; Fleurance R; Dardou D; Hafidi A; Nogueira da Costa A; Durif F
J Psychopharmacol; 2017 Oct; 31(10):1323-1333. PubMed ID: 28631520
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury.
Liu M; Bachstetter AD; Cass WA; Lifshitz J; Bing G
J Neurotrauma; 2017 Jan; 34(2):414-422. PubMed ID: 27142118
[TBL] [Abstract][Full Text] [Related]
16. Unilateral intranigral administration of β-sitosterol β-D-glucoside triggers pathological α-synuclein spreading and bilateral nigrostriatal dopaminergic neurodegeneration in the rat.
Soto-Rojas LO; Martínez-Dávila IA; Luna-Herrera C; Gutierrez-Castillo ME; Lopez-Salas FE; Gatica-Garcia B; Soto-Rodriguez G; Bringas Tobon ME; Flores G; Padilla-Viveros A; Bañuelos C; Blanco-Alvarez VM; Dávila-Ayala J; Reyes-Corona D; Garcés-Ramírez L; Hidalgo-Alegria O; De La Cruz-López F; Martinez-Fong D
Acta Neuropathol Commun; 2020 Apr; 8(1):56. PubMed ID: 32321590
[TBL] [Abstract][Full Text] [Related]
17. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
[TBL] [Abstract][Full Text] [Related]
18. Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2013 Sep; 252():24-31. PubMed ID: 23727149
[TBL] [Abstract][Full Text] [Related]
19. Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self-perpetuating crosstalk?
Vairetti M; Ferrigno A; Rizzo V; Ambrosi G; Bianchi A; Richelmi P; Blandini F; Armentero MT
Biochim Biophys Acta; 2012 Feb; 1822(2):176-84. PubMed ID: 22119596
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
